ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Sells $1,941,563.19 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

ANI Pharmaceuticals Stock Performance

ANIP stock traded up $1.53 during trading on Wednesday, hitting $59.39. 228,701 shares of the company’s stock traded hands, compared to its average volume of 218,832. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $70.81. The stock has a fifty day moving average price of $58.32 and a two-hundred day moving average price of $60.76. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -105.20 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. During the same quarter in the previous year, the firm earned $1.05 earnings per share. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ANIP. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Finally, Raymond James raised their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $77.33.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ANIP. SG Americas Securities LLC acquired a new position in shares of ANI Pharmaceuticals during the first quarter valued at $106,000. Vanguard Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 1.4% during the first quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock valued at $90,314,000 after acquiring an additional 17,460 shares during the period. O Shaughnessy Asset Management LLC acquired a new position in shares of ANI Pharmaceuticals during the first quarter valued at $218,000. CANADA LIFE ASSURANCE Co boosted its holdings in shares of ANI Pharmaceuticals by 7.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 13,036 shares of the specialty pharmaceutical company’s stock valued at $900,000 after acquiring an additional 909 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new stake in ANI Pharmaceuticals in the first quarter worth about $289,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.